Abstract
Much has changed in the medical treatment of COVID-19 after the first patient with an infection with SARS-CoV-2 in the Netherlands was diagnosed in February 2020. On the basis of limited data, at first only off-label use of (hydroxy)chloroquine seemed to be a treatment option. However, now based on the findings of several randomized studies, other medicines have been included in the Dutch guidelines about the treatment of COVID-19. In this article, we will briefly discuss the current state of affairs with regard to the drugs (hydroxy) chloroquine, remdesivir and corticosteroids. Again, it appears that only well-executed randomized clinical trials can determine the status of various supposedly effective drugs.
MeSH terms
-
Adenosine Monophosphate / analogs & derivatives*
-
Adenosine Monophosphate / pharmacology
-
Adenosine Monophosphate / therapeutic use
-
Alanine / analogs & derivatives*
-
Alanine / pharmacology
-
Alanine / therapeutic use
-
Anti-Inflammatory Agents / pharmacology
-
Anti-Inflammatory Agents / therapeutic use
-
Antiviral Agents / pharmacology
-
Antiviral Agents / therapeutic use
-
COVID-19 Drug Treatment*
-
COVID-19* / epidemiology
-
Drug Repositioning* / methods
-
Drug Repositioning* / standards
-
Glucocorticoids* / pharmacology
-
Glucocorticoids* / therapeutic use
-
Humans
-
Hydroxychloroquine* / pharmacology
-
Hydroxychloroquine* / therapeutic use
-
Netherlands / epidemiology
-
Randomized Controlled Trials as Topic
-
SARS-CoV-2 / drug effects*
-
Treatment Outcome
Substances
-
Anti-Inflammatory Agents
-
Antiviral Agents
-
Glucocorticoids
-
remdesivir
-
Adenosine Monophosphate
-
Hydroxychloroquine
-
Alanine